Navigation Links
Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Date:6/4/2008

SEATTLE, June 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Dr. Kendall Mohler, co-founder and senior vice president of research and development, is scheduled to present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference on June 12 at 10 a.m. EDT. This conference will be held at the New York Palace Hotel in New York City. The presentation will be available via audio webcast at http://www.wsw.com/webcast/needham25/trbn/ and will be available in the investors section of Trubion's website, investors.trubion.com.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Contact:

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788

amyp@waggeneredstrom.com

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Announces Presentations at April/May Investor Conferences
2. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
3. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
4. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
7. Onyx Pharmaceuticals to Present at Goldman Sachs 29th Annual Global Healthcare Conference
8. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
9. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
10. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
11. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... New York, NY (PRWEB) , ... May 03, 2016 , ... ... Lenox Hill Hospital , for definitive prostate cancer treatment, patients traditionally had two main ... an appropriate treatment plan would be made. , New technology has enabled doctors ...
(Date:5/2/2016)... YORK , May 2, 2016 ... announces that its technology partner Mannin Research Inc. will ... Ophthalmology (ARVO), which takes place from May 1-5, 2016 ... executives will be meeting with its vendors and research ... explore business development goals and other collaborative opportunities for ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... StarNet Communications ... today announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 ... desktops from Linux and Unix servers to the user’s PC over encrypted SSH. , ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team has ... team explored how bacterial properties can be applied to fabric and formed into living ... move in response to humidity change. The team harvested Natto cells and applied them ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):